Prolonged androgen deprivation leads to overexpression of calpain 2: Implications for prostate cancer progression

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 467-472

  Tiancheng, L I U ^a   Mendes, Desiree E ^a   Berkman, Clifford E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Androgen deprivation; Androgen receptor; Calpain 2; Filamin A; Prostate cancer

Indexed keywords

ANDROGENS; BLOTTING, WESTERN; CALPAIN; DIPEPTIDES; FILAMINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROSCOPY, CONFOCAL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 84894479503     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2196     Document Type: Article

References (34)

1. Gustavsson H, Welen K and Damber JE: Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364-373, 2005. (Pubitemid 40227488)
2. Niu Y, Altuwaijri S, Lai KP, et al: Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 105: 12182-12187, 2008.
3. Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H and Gao AC: Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate 67: 1293-1300, 2007. (Pubitemid 47435777)
4. Saraon P, Jarvi K and Diamandis EP: Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 57: 1366-1375, 2011.
5. Devlin HL and Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186, 2009.
6. Watson PA, Chen YF, Balbas MD, et al: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107: 16759-16765, 2010.
7. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ and Mudryj M: Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67: 9001-9005, 2007. (Pubitemid 47535881)
8. Cai C and Balk SP: Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 18: R175-R182, 2011.
9. Chang KH, Li R, Kuri B, et al: A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154: 1074-1084, 2013.
10. Liu T, Mendes DE and Berkman CE: From AR to c-Met: Androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int J Oncol 43: 1125-1130, 2013.
11. Hendriksen PJ, Dits NF, Kokame K, et al: Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66: 5012-5020, 2006. (Pubitemid 43844921)
12. Lorenzo GD, Bianco R, Tortora G and Ciardiello F: Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2: 50-57, 2003. (Pubitemid 37012422)
13. Maeda A, Nakashiro K, Hara S, et al: Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun 347: 1158-1165, 2006. (Pubitemid 44118235)
14. Nishida S, Hirohashi Y, Torigoe T, et al: Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci 104: 431-436, 2013.
15. Storr SJ, Carragher NO, Frame MC, Parr T and Martin SG: The calpain system and cancer. Nat Rev Cancer 11: 364-374, 2011.
16. Camins A, Verdaguer E, Folch J and Pallas M: Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 12: 135-148, 2006. (Pubitemid 44300381)
17. Lakshmikuttyamma A, Selvakumar P, Kanthan R, Kanthan SC and Sharma RK: Overexpression of m-calpain in human colorectal adenocarcinomas. Cancer Epidemiol Biomarkers Prev 13: 1604-1609, 2004. (Pubitemid 39331881)
18. Kimura Y, Koga H, Araki N, et al : The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat Med 4: 915-922, 1998. (Pubitemid 28364030)
19. Mamoune A, Luo JH, Lauffenburger DA and Wells A: Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res 63: 4632-4640, 2003. (Pubitemid 36951041)
20. Rios-Doria J, Day KC, Kuefer R, et al: The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 278: 1372-1379, 2003. (Pubitemid 36790823)
21. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW and Ghosh PM: A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene 26: 6061-6070, 2007. (Pubitemid 47373811)
22. Yue J, Huhn S and Shen Z: Complex roles of filamin-A mediated cytoskeleton network in cancer progression. Cell Biosci 3: 7-18, 2013.
23. Bedolla RG, Wang Y, Asuncion A, et al: Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res 15: 788-796, 2009.
24. Chen H, Libertini SJ, Wang Y, Kung HJ, Ghosh P and Mudryj M: ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem 285: 2368-2374, 2010.
25. Liu T, Wu LY, Fulton MD, Johnson JM and Berkman CE: Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol 41: 2087-2092, 2012.
26. Matroule JY, Carthy CM, Granville DJ, Jolois O, Hunt DW and Piette J: Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene 20: 4070-4084, 2001. (Pubitemid 32681612)
27. Liu T, Wu LY and Berkman CE: Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett 296: 106-112, 2010.
28. Liu T, Toriyabe Y and Berkman CE: Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 49: 251-255, 2006. (Pubitemid 44416227)
29. Chan KT, Bennin DA and Huttenlocher A: Regulation of adhesion dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK). J Biol Chem 285: 11418-11426, 2010.
30. Franco SJ, Rodgers MA, Perrin BJ, et al: Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat Cell Biol 6: 977-983, 2004. (Pubitemid 39359850)
31. Kwak HI, Kang H, Dave JM, et al: Calpain-mediated vimentin cleavage occurs upstream of MT1-MMP membrane translocation to facilitate endothelial sprout initiation. Angiogenesis 15: 287-303, 2012.
32. Jang HS, Lal S and Greenwood JA: Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2. Neurochem Res 35: 1796-1804, 2010.
33. Postovit LM, Dutt P, Dourdin N, et al: Calpain is required for MMP-2 and u-PA expression in SV40 large T-antigen-immortalized cells. Biochem Biophys Res Commun 297: 294-301, 2002. (Pubitemid 35216169)
34. Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM and Landowski TH: Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol 71: 1567-1576, 2013.